NK Cell Metabolism and TGFβ – Implications for Immunotherapy

Karen Slattery* and Clair M. Gardiner*

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland

NK cells are innate lymphocytes which play an essential role in protection against cancer and viral infection. Their functions are dictated by many factors including the receptors they express, cytokines they respond to and changes in the external environment. These cell processes are regulated within NK cells at many levels including genetic, epigenetic and expression (RNA and protein) levels. The last decade has revealed cellular metabolism as another level of immune regulation. Specific immune cells adopt metabolic configurations that support their functions, and this is a dynamic process with cells undergoing metabolic reprogramming during the course of an immune response.

Upon activation with pro-inflammatory cytokines, NK cells upregulate both glycolysis and oxphos metabolic pathways and this supports their anti-cancer functions. Perturbation of these pathways inhibits NK cell effector functions. Anti-inflammatory cytokines such as TGFβ can inhibit metabolic changes and reduce functional outputs. Although a lot remains to be learned, our knowledge of potential molecular mechanisms involved is growing quickly. This review will discuss our current knowledge on the role of TGFβ in regulating NK cell metabolism and will draw on a wider knowledge base regarding TGFβ regulation of cellular metabolic pathways, in order to highlight potential ways in which TGFβ might be targeted to contribute to the exciting progress that is being made in terms of adoptive NK cell therapies for cancer.

Keywords: NK cells, metabolism, mitochondria, TGFβ, immunotherapy

THE IMPORTANCE OF IMMUNOMETABOLISM

Over the past decade, the field of immunometabolism has exploded and become one of the fastest growing research areas in immunology. We now appreciate the vast impact that metabolism has on the fate and function of immune cells, although we are far from fully understanding it. The metabolic status of a cell dictates the functions that it can carry out e.g., increased mitochondrial mass and high rates of fatty acid oxidation are fundamental for memory T cells to carry out their antigen recall response (1). Immunometabolism has reinvigorated many areas of research and allowed older concepts to be viewed in a new light.

Importantly, immunometabolism is having an impact in the clinic. The effect that old drugs have on the metabolism of immune cells is now being explored for the first time. For example, metformin, which has been used to treat type 2 diabetes for many decades, works by inhibiting complex I in the electron transport chain and hence can strongly impact immune cells that use oxidative metabolism to carry out their functions (2). Indeed, recent research has shown that metformin can skew T cell differentiation toward regulatory and memory T cells (3). Another
example is the deeper understanding provided by metabolism of how checkpoint inhibitors work during cancer therapy. Bengsch et al. demonstrated that anti-PDL1 therapy reprogrammed metabolism of exhausted T cells and improved several readouts of mitochondrial structure and function as part of the mechanisms of action of this therapy (4). It is likely that these checkpoint inhibitors are also impacting the metabolism of Natural Killer (NK) cells, as NK cells also express some of these checkpoint antigens (5).

Many of the new concepts in immunometabolism have been inspired by the more advanced field of cancer metabolism. For nearly a century we have been aware of the metabolic reprogramming that takes place in tumor cells (6), and this has resulted in the development of drugs that target tumor cell metabolism e.g., methotrexate, an inhibitor of dihydrofolate reductase, that has been used in chemotherapy since the 1940s (7). These drugs were designed based almost exclusively on research on tumor cell metabolism and their potential impact on immune cells was not investigated or considered. However, as we increasingly turn to the immune system for new cancer therapy approaches, a trend likely to continue given the high rewards yielded to date, cancer researchers and immunologists need to work together to consider the consequences of strategies proposed for synergy to be achieved. For example, rapamycin [a mammalian target of rapamycin complex 1 (mTORC1) inhibitor], is currently in clinical trials for neuroblastoma (ClinicalTrials.gov; NCT01331135) and for breast cancer (ClinicalTrials.gov; NCT02536625). We predict that this therapy will severely inhibit NK cell and other cytotoxic immune cell responses, which are highly dependent on mTORC1 mediated metabolic reprogramming to carry out their functions. This is particularly concerning for patients where antibody mediated therapy is part of their standard treatment of care e.g., anti-GD2 therapy for high risk neuroblastoma and trastuzumab for HER2 breast cancer, and which works in part by promoting NK cell antibody dependent cellular cytotoxicity (ADCC) (8). We are only now beginning to understand the off-target effects that these metabolic cancer therapies have on the immune system and a current goal of the field is trying to figure out ways in which we can selectively target cancer metabolism while protecting the anti-tumor immune response.

What is more exciting, however, is that immunometabolism research is revealing new drug targets that may prove effective in the treatment of a variety of human diseases. As we now know that metabolic inhibitors such as 2-deoxyglucose (2DG) can inhibit the immune response, the potential for these to be used in preventing graft rejection is under investigation, and pre-clinical results from mouse models are very promising (9). Sukumar et al. showed that inhibiting glycolytic metabolism in CD8+ T cells increases the generation of memory cells and their anti-tumor functions (10), while Fischino et al. showed that improving mitochondrial fitness using antioxidants is sufficient to revive exhausted CD8+ T cells and increase their antiviral functions (11). In human sepsis patients, IL-7 treatment increases glucose metabolism and mTOR activity in dysfunctional T cells (12). Overall, it seems likely that some of these immunometabolism-derived therapies will reach clinical trials in the near future.

**SPECIFIC IMMUNE CELLS ADOPT PARTICULAR METABOLIC CONFIGURATIONS**

Indeed, there is a growing appreciation of the extent to which immunometabolism underpins many aspects of the immune response. Different immune cells have specialized metabolic configurations that allow them to carry out their specialized functions. In general, these pathways provide both energy (in the form of adenosine tri-phosphate; ATP) and biosynthetic precursor molecules that will be required for carrying out their effector functions. Various fuels can be used by cells including glucose, glutamine and fatty acids. As mentioned, memory T cells mainly engage in fatty acid oxidation. Fatty acid oxidation involves the breakdown of cellular fatty acids into smaller components which can then go into the mitochondria of the cell where they feed the tricarboxylic acid (TCA) cycle to facilitate NADH and FADH₂ production (see Figure 1 for main cell energy production pathways) which are required to supply electrons to the mitochondria. This final process called oxidative phosphorylation (or ophos) consumes oxygen and results in production of ATP. Unlike glucose, fatty acids can easily be stored as lipid droplets within the cell. As such, memory T cells synthesize fatty acids so that they can rapidly oxidize the stored fatty acids which then supplies the energy required for the recall response (13). Similarly, regulatory T cells use fatty acid oxidation to support their long life span (14). Other immune cells, with different functions, use alternative forms of metabolism. At rest, most naïve immune cells carry out ophos to meet their homeostatic needs. Once an immune cell becomes activated, it reprograms cellular metabolism to suit its functions. In many cell types, this involves upregulation of glycolysis, the key pathway in glucose metabolism. This increased glycolytic flux supports rapid ATP synthesis in addition to production of various biosynthetic precursors such as amino acids (15). As this upregulation of glycolysis takes place in the presence of oxygen, it is known as aerobic glycolysis, and is fundamental for the functions of NK cells, effector T cells, B cells, dendritic cells (DC), neutrophils, and M1 macrophages (16). By understanding how these metabolic pathways support functions of the immune response, we can aspire to unlock new ways in which to control and regulate the immune system therapeutically.

**Abbreviations:** NK, Natural Killer; mTORC1, Mammalian target of rapamycin complex 1; ADCC, Antibody dependent cellular cytotoxicity; 2DG, 2-deoxyglucose; TCA, Tricarboxylic acid; DC, Dendritic cell; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; ROS, Reactive oxygen species; PGC-1α, Proliferator-activated receptor gamma coactivator 1-alpha; SREBP, Sterol regulatory element-binding protein; IRE1, Inositol-requiring enzyme 1; TGFβR2, TGFβ receptor 2; TGFβR1, TGFβ receptor 1; FBP1, Fructose-1,6-bisphosphatase; AML, Acute myeloid leukemia; MDS, Myelodysplastic syndrome; iPSC, Induced pluripotent stem cells; SOD, Superoxide dismutase; NAC, N-acetylcysteine; NOX4, NADPH oxidase 4; UCP2, Uncoupling protein 2; ER, Endoplasmic reticulum; PGASMC, Preglomerular afferent arteriolar smooth muscle cells; CAR, Chimeric antigen receptor; FDA, Food and Drug Administration; ATP, Adenosine tri-phosphate.
NK CELL METABOLISM

NK cells have characteristic metabolic configurations which facilitate their functions. Oxphos is used to meet their homeostatic needs, and after short term stimulation (6 h) oxphos remains the dominant form of metabolism (17). However, when activated over longer periods of time (18h+), NK cells upregulate both oxphos and glycolysis, with their main form of metabolism shifting to glycolysis (18, 19). This shift allows for production of biosynthetic precursors that are needed for NK cells to carry out their functions and may also serve to enhance their longevity and thus their ability to function in parallel with the adaptive immune system.

Metabolic tracing experiments have revealed that NK cells adopt a unique metabolic configuration, whereby they use the citrate-malate shuttle to fuel oxphos (Figure 2). Instead of cycling citrate through the TCA cycle like most cells, they export it to the cytosol where it is then converted to acetyl CoA and oxaloacetate (20). The acetyl CoA can then be used for acetylation reactions (important for innate immune training) or to produce fatty acids, while the oxaloacetate is converted back to malate and then shuttled back to the TCA cycle. Ultimately, this results in the production of cytosolic NAD^+, which is an essential cofactor for the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and NADH, which is fed into the electron transport chain support ATP production. This facilitates increases in both glycolysis and oxphos which are required for the NK cell functional response.

At the mitochondrial level, cytokine stimulation can also induce significant changes. Miranda et al. looked at IL2 induced mitochondrial changes in human NK cells (21). They showed that IL2 stimulation increased both the mitochondrial mass and the mitochondrial membrane potential. This was dependent on the expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and its deletion resulted in reduced mitochondrial mass and membrane polarization, in addition to impaired IFNγ production. Abarca-Rojano et al. showed that the mitochondria of NK cells depolarize upon contact with a tumor cell, and that they reorganize themselves to the point of contact with the cancer cell (22). It has also been shown that mitophagy, i.e., the removal of defective mitochondria, is essential for the development of NK cell memory (23). Interestingly, this process occurs in a reactive oxygen species (ROS) dependent manner.

REGULATION OF NK CELL METABOLISM

The complex metabolic configuration of NK cells requires a high degree of regulation. As with many immune cells, several aspects of NK cell metabolism are highly dependent on mTORC1, a protein complex that functions as a nutrient/metabolic sensor and coordinates protein synthesis. mTORC1 activity increases upon cytokine stimulation of NK cells and enhances glycolytic flux through the cells. Inhibition of mTORC1 using rapamycin results in inhibition of cell size, nutrient receptor expression...
Slattery and Gardiner TGFβ and NK Cell Metabolism

FIGURE 2 | NK cell metabolism. Activated NK cells metabolize glucose to pyruvate. Pyruvate is converted to acetyl CoA which is then converted into citrate. Citrate is exported into the cytosol via SLC25A1, where it is converted into oxaloacetate and acetyl CoA. Acetyl CoA can then be used in acetylation reactions or for lipid synthesis. Oxaloacetate is converted back in malate, resulting in the production of NAD⁺, and essential cofactor for glycolysis. Malate is transported back into the mitochondria, where it is converted back into oxaloacetate, producing NADH which can then feed into the electron transport chain for ATP synthesis.

Beyond mTOR signaling, NK cells have quite unique underlying regulatory mechanisms. Sterol regulatory element-binding protein (SREBP) is a transcription factor known traditionally for its role in fatty acid and cholesterol synthesis. However, in NK cells, SREBP is fundamental for the modulation of glycolysis and oxphos. This is partly due to regulated expression of the main transporter involved in the citrate-malate shuttle—SLC25A1 (20). Unsurprisingly, inhibition of SREBP also inhibits NK cell functions.

cMyc is another transcription factor that has been shown to be essential for NK cell metabolism (27). In this setting, cMyc is acutely controlled by the availability of amino acids. These amino acids, glutamine in particular, are imported into the cell via the transporter SLC7A5 where they then turn on cMyc and allow it to regulate NK cell metabolism and function. Interestingly, neither HIF1α nor glutaminolysis were shown to be important for NK cell metabolism in this study, which is in contrast to other cytotoxic lymphocytes. Dong et al. has recently shown that inositol-requiring enzyme 1 (IRE1), an ER-nucleus signaling protein, is essential for optimal NK cell anti-tumor and anti-viral responses and works by directly regulating cMyc activity (28).

TGFβ

As proinflammatory cytokines such as IL2, IL12, and IL15 induce robust NK cell metabolic responses like those described above, anti-inflammatory cytokines can also inhibit them. For decades, many studies have reported on the negative effects that TGFβ has on NK cell functions (29–31). TGFβ is a pleiotropic cytokine and can play a role in a wide variety of processes, including differentiation, migration, apoptosis, wound healing and angiogenesis (32). While TGFβ is generally acknowledged as a negative regulator of growth (e.g., via inhibition of cMYC and CDKs) (33), it can also promote proliferation of certain cells (e.g., mesenchymal stem cells) (34).

The TGFβ canonical signaling pathway is relatively simple—TGFβ first binds to TGFβ receptor 2 (TGFβR2), which leads
to the recruitment, transphosphorylation and activation of TGFβ receptor 1 (TGFβR1). TGFβR1 then phosphorylates its downstream targets using its cytoplasmic kinase domain to initiate the SMAD dependent signaling pathway [5]. Phosphorylated SMAD2 and SMAD3 bind to SMAD4 and the complex then travels to the nucleus where it modulates gene expression and directs the cells response to TGFβ. SMAD6 and SMAD7 are negative regulators of this pathway, and their expression may be induced by SMAD4-2/3 forming a negative feedback loop (35). Ubiquitination of TGFβ signaling molecules is a common way in which this pathway is regulated (36).

Although there are relatively few SMAD proteins involved in TGFβ signaling, they commonly regulate gene expression in cooperation with hundreds of high affinity DNA-binding transcription factors and transcription coregulators. These are controlled by and often dependent on other signaling pathways, resulting in highly context-dependent transcriptional responses being controlled by signaling cross talk (37, 38).

Alternatively, TGFβ ligands can signal through non-SMAD (“non-canonical”) signaling pathways. This entails recruitment and activation of signaling mediators by ligand-occupied receptors i.e., TGFβR1 and TGFβR2 (39). These pathways include branches of PI3K-Akt signaling which activate the MAPK pathway and mTOR, small GTPase pathway, JNK/p38 pathway, and can be regulated by phosphatases such as PP2A (39–41). Many of the signaling molecules in these pathways interact directly with TGFβR1 and/or TGFβR2 e.g., TRAF6 (42, 43). Of note, while the impact of TGFβ canonical signaling on NK cells is well described, the effect of TGFβ non-canonical signaling on NK cells remains largely unexplored.

**TGFβ AND NK CELL METABOLISM**

While it has been known for many decades that TGFβ inhibits the activity and functions of NK cells (30, 44, 45), the molecular mechanisms underlying this have remained poorly understood. Scientists are beginning to investigate these and immunometabolism studies may help shed some light on this topic. Viel et al. showed that while TGFβ had no effect on the development of murine NK cells, genetic deletion of the TGFβR2 (specifically in NK cells via Ncr1Cre mice crossed with TGFβR2fl/fl mice) reduced tumor metastasis in two tumor models and increased nutrient receptor expression and mTORC1 activity in IL15 stimulated NK cells (46). In vitro, TGFβ treatment inhibited mouse and human metabolic responses (oxphos and glycolysis), nutrient receptor expression and mTORC1 activity. Rapamycin treatment recapitulated most of the effects of TGFβ treatment. In many cases, the effects of TGFβ were more potent than those of rapamycin, yet mTORC1 deletion had more significant effects than constitutive TGFβ signaling, suggesting that mTORC1 is not the only pathway involved in the repression of NK cell activity by TGFβ.

Work from our lab also investigated the effect of TGFβ on human NK cells stimulated with cytokine (47). We showed that NK cells stimulated with IL2 for 18 h in the presence of TGFβ had significantly reduced levels of oxphos, maximal respiration and glycolytic capacity. Interestingly, glycolysis was not affected. Furthermore, the expression of CD69, CD71 and the functional mediators IFNγ and granzyme B were also reduced following TGFβ treatment. With the exception of granzyme B, these effects were reversed by adding a TGFβR1 inhibitor, suggesting that TGFβ’s impact on granzyme B is mediated by an alternative pathway, likely one of the non-canonical pathways that signals through TGFβR2 only. Indeed, deletion of the TGFβR2 (specifically in NK cells) has been shown to reduce granzyme B expression in murine NK cells (46).

In contrast to Viel et al. we observed that TGFβ had no impact on NK cell mTORC1 activity (at 30 min, 1 or 18 h). However, if the NK cells were exposed to TGFβ for a prolonged period of time (5 days), TGFβ reduced IL2 induced mTORC1 activity. There are several potential explanations for the discrepancies between these two studies. First and foremost, the vast majority of the Viel et al. study was carried out on murine NK cells. In that study, the impact of TGFβ on human NK cell mTORC1 activity was evident in only some donors and was modest compared to its effect on murine NK cell mTORC1 activity. Finally, the timepoints (mainly 1 vs. 18 h) and cytokine stimulations (IL15 vs. IL12/15) differed between the studies, precluding direct comparisons.

In contrast to both above studies, there are many reports showing that TGFβ actually activates mTORC1 (and mTORC2) in non-immune cells. Rahimi et al. showed that TGFβ activates mTORC1 mediated growth in fibroblasts (but not epithelial cells), and that mTORC2 is required for TGFβ mediated Akt signaling (48). More recently it was shown that TGFβ promotes mTORC1 mediated GLUT1 expression and glycine biosynthesis in human lung fibroblasts, which culminates in collagen production and fibrosis (49). Similarly, others have reported that TGFβ induces mTORC1 activity and subsequent HIF1α activity and collagen expression in human kidney cells (50, 51). Cheng et al. showed that TGFβ induced epithelial-mesenchymal transition cell proliferation and migration is dependent on mTORC1 in cervical carcinoma cells (52). Indeed, it seems there is still a lot to be learned about the relationship between TGFβ and mTORC1 (and mTORC2) signaling. It will be interesting to see in the future whether TGFβ affects the mTORC1 activity of different immune cells in distinct ways.

Beyond the interplay of TGFβ and mTORC1, another study has demonstrated the impact of TGFβ on the expression of the anabolic enzyme fructose-1,6-bisphosphatase (FBP1) in murine NK cells (53). FBP1 is an essential enzyme in gluconeogenesis, a pathway which results in the generation of glucose from non-carbohydrate substrates such as amino acids, triglycerides and lactate. FBP1 hydrolyses fructose 1,6-bisphosphate into fructose 6-phosphate, thus reversing the direction of the glycolysis pathway and promoting glucose synthesis. While gluconeogenesis is traditionally known to take place in the liver and serve to maintain blood glucose levels, this study showed that TGFβ treatment (24 h) increased the expression of FBP1 mRNA in murine lung NK cells, which induced NK cell dysfunction and tumor progression. Whether TGFβ has such effects on other glycolytic/metabolic enzymes
in NK cells is yet to be investigated. This could potentially shed light on TGF\(\beta\) induced metabolic defects described in the above studies.

Recent work from our lab showed that peripheral blood NK cells from patients with metastatic breast cancer have severely reduced levels of metabolism and impaired mTORC1 activity (54). Neutralization of TGF\(\beta\) _ex vivo_ restored levels of oxphos, mTORC1 activity, nutrient receptor expression and importantly, IFN\(\gamma\) production. TGF\(\beta\) neutralization did not restore IL2 induced glycolysis—however, we previously reported that TGF\(\beta\) treatment had no effect on glycolysis in human NK cells (47). Hence, TGF\(\beta\) does not seem to impact oxphos and glycolysis in the same manner. The overnight restoration of various metabolic and functional parameters of NK cells from breast cancer patients gives promise to the various TGF\(\beta\) targeted therapies currently in development.

**POTENTIAL ROLES FOR TGF\(\beta\) IN REGULATING NK CELL METABOLISM**

While research on the role of TGF\(\beta\) regulating NK cell metabolism is in its infancy, there is a vast body of literature detailing the impact of TGF\(\beta\) on metabolism in other cell types. Given the complexity of TGF\(\beta\) signaling and its pleiotropic effects on many different cell types, these studies are unlikely to provide a simple understanding of what is happening in NK cells. However, they provide a strong starting point and illustrate several molecular mechanisms which may underlie TGF\(\beta\)'s negative impact on NK cell metabolism and function. Here, we consider some key examples of how TGF\(\beta\) might be affecting NK cell cellular metabolism and suggest ways in which we might use this knowledge to improve immunotherapy (see Figure 3).

**TGF\(\beta\) and cMyc**

As described above, cMyc is an important regulator of NK cell function and metabolism (27). It has long been known that one of the main ways in which TGF\(\beta\) acts as a growth repressor is via inhibition cMyc (55). Indeed, TGF\(\beta\) has been shown to inhibit cMyc expression via the canonical signaling pathway in several cell types including keratinocytes (56), tumor cell lines (57, 58) and oligodendrocyte progenitors (59). Hence, it is possible that TGF\(\beta\) is affecting cMyc expression in NK cells and that this is contributing to the reduced metabolism and functions observed in (46) and (47). Interestingly, Zakiryanova et al. recently reported reduced cMyc expression in NK cells from human lung and gastric cancer patients. As we know that TGF\(\beta\) levels are commonly increased in patients with these cancers (60–62), TGF\(\beta\)-mediated cMyc inhibition may be an underlying cause for the NK cell dysfunction observed in these cancers (53, 63, 64). If this is the case, alleviating cMyc suppression may bypass some of the inhibitory effects that TGF\(\beta\) is having on NK cell metabolism. For example, increasing the availability of amino acids will stabilize cMyc, or inhibition of glycogen synthase kinase 3 will reduce cMyc degradation. Both approaches have previously been shown to increase NK cell activity and function in mice and humans (27, 65, 66).

TGF\(\beta\) itself has not been shown to directly regulate the activity of SREBP (another essential regulator of NK cell metabolism). However, there are several reports showing that SREBP regulates TGF\(\beta\) activity in kidney cells (67–69). Thus, it is interesting to speculate that there may be a role for altered SREBP activity in NK cells leading to dysregulated TGF\(\beta\) activity in cancer.

**TGF\(\beta\) and ROS**

ROS are highly reactive, oxygen containing molecules such as \(O_2^-\), \(OH^-\) and \(H_2O_2\). They are produced in the cytosol, e.g., as a by-product of NADPH oxidase enzymes, or in the mitochondria,

---

**Figure 3** | Potential roles for TGF\(\beta\) in regulating NK cell metabolism. TGF\(\beta\) has been shown to impact the metabolism of various non-immune cell types. This included reduced cMyc activity, reduced ER-mitochondrial signaling, increased ROS and reduced antioxidants, increased mitochondrial membrane potential and increased mitochondrial mass.
cells express various antioxidant proteins such as superoxide dismutase (SOD) and catalase which can convert ROS into water and oxygen. ROS can be produced under homeostatic conditions and are involved in many biological processes such as redox signaling pathways and apoptosis. In murine NK cells, they play an essential role in the generation of NK cell anti-viral memory (23). However, excessive ROS can be very harmful for a cell as the ROS can react with and damage various cellular components such as DNA and protein. Excessive ROS may also result in aberrant cell signaling through oxidative modification of redox-sensitive signaling proteins e.g., MAPK, HIF or NFKB (70). Recent studies showed that excessive ROS production is associated with NK cell metabolic dysfunction in metastatic breast cancer patients and in childhood obesity (54, 71). Interestingly, there is significant evidence demonstrating a connection between TGFβ and ROS production, with TGFβ treatment stimulating ROS production in many different studies.

The ability of Treg cells to suppress proliferation of T effector cells was enhanced by TGFβ treatment, and this was reversed via the addition of the antioxidant n-acetylcysteine (NAC) or via the antioxidant system of NK cells and that this may be altering their function and/or metabolism. If this proves to be true, modulating NK cells such that they are more resistant to oxidative stress (e.g., by pre-treating with antioxidants or overexpressing antioxidant enzymes such as SOD2) may help them to cope with TGFβ induced ROS. Hence, in a TGFβ rich environment such as the tumor microenvironment, modified NK cells will be more resistant to oxidative damage and more able to fight the tumor. Interestingly, pre-treatment of exhausted CD8+ T cells with antioxidants has been shown to restore their antiviral activity (11) during human chronic hepatitis B infection, where systemic increases in TGFβ have been reported (79, 80).

The interplay between TGFβ and ROS is of particular interest in the context of murine NK cell memory where we know ROS plays a major role (23). Here, ROS production is required for the removal of defective mitochondria and the development of NK cell anti-viral memory. Perhaps in this case, TGFβ might play a positive role by stimulating ROS production in faulty NK cells and promoting their clearance by mitophagy.

**TGFβ and Mitochondrial Structure and Function**

It is widely acknowledged that TGFβ plays a key role in regulating mitochondrial apoptosis (81), and as described above, TGFβ can stimulate mitochondrial ROS production in a variety of cell types. However, there are many other ways in TGFβ can modulate mitochondrial activities. TGFβ was reported to increase mitochondrial mass in primary human lung fibroblasts (82). In this study, TGFβ signaling via the canonical pathway culminated in the upregulation of PGC-1α expression. Interestingly, PGC-1α mediated increases in mitochondrial mass and polarization has been shown to be essential for NK cell IFNγ production (21).

Mitochondrial membrane potential is the electronegative force across the inner mitochondrial membrane that drives ATP production using ATP synthase. Yoon et al. reported that TGFβ increased the mitochondrial membrane potential of lung epithelial cells, yet interestingly did not alter secretion of apoptotic factors from the mitochondria (76). Similarly, TGFβ has been shown to increase mitochondrial membrane potential in mouse kidney cells (83). Indeed, it is tempting to speculate that the increased mitochondrial mass and membrane potential observed in NK cells from metastatic breast cancer patients is in part due to increased TGFβ activity (54). In breast cancer cells, TGFβ has been shown to regulate expression of mitochondrial uncoupling protein 2 (UCP2), a mitochondrial transporter involved in dissipation of the mitochondria membrane potential to facilitate heat production (84).

As discussed, NK cells treated with TGFβ have reduced levels of oxphos and maximal respiration (47). This has also been shown in hepatocellular carcinoma cells, where TGFβ treatment skewed metabolism away from oxphos in order to promote the epithelial/mesenchymal cell transition (85). Interestingly, the expression of SLC7A5 was increased in the cancer cells in response to TGFβ. As we know that this transporter is essential for NK cell metabolism (27), is it possible that TGFβ may also affect the activity of SLC7A5 in NK cells. Overall, it seems clear that TGFβ is directly inhibiting NC cell oxphos and that this is impacting upon their anti-tumor functions. This is likely due to its effects on mitochondrial structure and function such as those described above. Targeting NK cell mitochondrial structure could help restore any TGFβ-induced mitochondrial defects. For example, Buck et al. showed that increasing mitochondrial fusion increases oxphos and anti-tumor functions in T cells (86). This treatment also increased the efficacy of adoptive cell therapy in a model of T cell lymphoma. Similarly, increasing mitochondrial fusion has been shown to increase oxphos in TGFβ and IL10 treated B cells (87). Another way to circumvent the inhibitory effect of TGFβ on oxphos might be to increase the supply of nutrients which can be metabolized by other pathways or to promote mTORC1 activity which preferentially skews metabolism toward glycolysis (e.g., by increasing the availability
of amino acids), which seems to be more resistant to TGFβ's negative effects.

Finally, TGFβ has been shown to regulate mitochondrial-endoplasmic reticulum (ER) calcium signaling (88). Under normal conditions, Ca²⁺ is transferred from the ER to the mitochondria where it stimulates ATP production by increasing the activity of electron transport chain dehydrogenase enzymes and increasing proton pumping across the inner membrane. However, treatment of single preglomerular afferent arteriolar smooth muscle cells (PGASMC) with TGFβ reduces the Ca²⁺ release from the ER and impairs the mitochondrial-ER coupling. Indeed, there is evidence supporting the role of calcium in modulating NK cell functions. NK cells from patients with a deficiency in calcium channels have severely impaired degranulation and killing capacity in vitro (89). Similarly, Ca²⁺ channel agonists/antagonists have also been shown to inhibit NK cell degranulation and killing capacity (90). Goodridge et al. recently showed that interfering with Ca²⁺ stores reduces degranulation and IFNγ production in human NK cells (91). It seems likely that an interplay between Ca²⁺ signaling, metabolism and function exists in NK cells. The nature of this and the possible role that TGFβ plays in regulating this axis awaits experimental elucidation.

**NK CELL IMMUNOTHERAPY**

NK cells are exploited in a variety of ways therapeutically including as an adoptive cell therapy for cancer. Investigation of NK cell metabolism has the potential to improve this increasingly popular approach. While most studies on adoptive cell therapy have focused on T cells, NK cells offer several advantages (see Figure 4). Unlike T cells, NK cells are generally considered to not be antigen specific, and as such it is more challenging for a tumor to escape the NK cell immune response by antigen mutation alone (92). Importantly, NK cells are less likely to induce graft-vs.-host disease (93), and can positively promote a graft vs. leukemia effect (94, 95). Similarly, NK cells are less likely to promote cytokine release syndrome (96), which has occasionally proven fatal in the context of T cell therapy (97).

As discussed, there is a plethora of ways in which TGFβ is/might be impacting the metabolism of NK cells. This suggests that by blocking the interaction between NK cells and TGFβ we might be able to protect their metabolism and function in TGFβ rich environments, such as those found in cancer. For example, Yvon et al. engrafted a dominant-negative TGFβR2 onto cord blood derived NK cells, leaving them resistant to the inhibitory effects of TGFβ treatment and more efficient at killing glioblastoma tumor cells (98).
be effective in the breast cancer setting in vitro (99). Similarly, Daher et al. deleted the TGFβR2 in PBMC-derived NK cells using CRISPR-CAS9, rendering them resistant to TGFβ and more able to combat a xenograft model of myeloid leukemia (100). We predict that these genetic modifications also enhanced NK cell metabolism, and that this supported the improved anti-tumor immune responses recorded.

While autologous (targeting a patient’s own NK cells) NK cell transfer has proven to be safe and well tolerated (101), the most promising anti-tumor responses have been reported with allogeneic (third party) NK cell therapy. This is perhaps because autologous NK cells from cancer patients are often dysfunctional compared to NK cells from healthy individuals. In the case of allogeneic therapy, there have been many promising reports in recent years demonstrating the potential of the treatment. In poor prognosis acute myeloid leukemia (AML) patients, NK cell infusions in combination with high dose chemotherapy and IL2 infusion resulted in in vivo expansion of NK cells and complete hematologic remission in 5 out of 19 patients (102). Similar results were more recently shown in elderly high risk AML patients (103), and in high-risk myelodysplastic syndrome (MDS), and again in AML patients (104), where alloreactive NK cells were found in the periphery of all patients and in the bone marrow of some. In neuroblastoma, high doses of NK cell infusions followed by anti-GD2 immunotherapy improved progression free survival, and patient NK cells had increased NKG2A expression (105). In all studies, NK cell infusions were well tolerated, with no reported toxicities. These NK cells were primarily sourced from haploidentical donors i.e., matched for HLA on one chromosome (typically a related donor).

**Future Directions**

Indeed, we are in an exciting era of cellular therapy, and basic research such as that described herein will play an essential role in allowing us to harness these new technologies optimally. With the recent advances in genetic engineering, the future possibilities for NK cell immunotherapy are unlimited. Chimeric antigen receptor (CAR)-NK cells are undergoing intense research and are being tested currently in numerous clinical trials for various hematological and solid malignancies (Table 1). So far studies on CAR-NK cells, which have a modified version of surface receptor(s) that allow them to target tumors more efficiently, have been very promising.

Li et al. engineered iPSC derived NK cells and T cells to express a CAR construct consisting of the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain (CD244), and the CD3γ signaling domain (106). These highly active CAR-NK cells and CAR-T cells both exhibited enhanced anti-tumor activity in a murine model of ovarian cancer compared to their non-CAR counterparts. However, the CAR-T cell therapy had significant toxicities which the CAR-NK cell therapy did not e.g., sustained increases in plasma IFNγ, TNFα, and IL2 levels, and pathogenic organ damage in infiltrated organs. At day 70 post treatment, 4/5 mice which received CAR-NK cell therapy were still alive, vs. just 1/5 mice which received CAR-T cell therapy. Similarly, Quintarelli et al. transduced CD19 into ex vivo expanded healthy donor NK cells (107), thus allowing them to specifically target transformed B cells. Transfusion of CAR-CGD19-NK cells resulted in 100% overall survival vs. 20% for CAR-CGD19-T cells in a xenograft model of leukemia in immunodeficient mice. Furthermore, cord blood derived CAR-CGD19-NK cells, also transduced with IL15, significantly prolonged survival in a xenograft model of lymphoma (108). There is potential to engineer these CAR-NK cells further to include a modification that boosts metabolism (e.g., increased mTORC1/GAPDH/SLC25A1) or reduces susceptibility to TGFβ (such as those described above).

An important consideration when contemplating new cancer therapies is the economical and physical feasibility of them. Isolation of NK cells from PBMC or stem cells is costly and time-consuming. As such, there is renewed focus on generating “off-the-shelf” NK cell therapies i.e., a relatively unlimited, generic supply of NK cells that can be banked and then infused into patients when needed. There are several biotechnology companies actively pursuing this therapeutic approach. Interestingly, this idea seems to be moving in the opposite direction to the popular model of “personalized medicine.” NK-92 is a transformed cell line derived from a human NK cell lymphoma patient, and they are known to spontaneously kill cancer cells via direct cytotoxicity and cytokine production. NK-92 cells have also been Food and Drug Administration (FDA) approved for use in clinical trials in 2017 (109). Since then, NK-92 infusions have proven to be well tolerated with only minor toxicities reported in clinical trials for lymphoma and multiple malignancies.

**Table 1 | CAR-NK cell clinical trials.**

| Cancer type                                      | CAR-NK cell therapy                                                                 |
|-------------------------------------------------|--------------------------------------------------------------------------------------|
| Anti-CD22 CAR-NK cells                          | Refractory B-cell lymphoma                                                           |
| Anti-CD19 CAR-NK cells                          | Refractory B-cell lymphoma                                                           |
| Anti-CD19/CD22 CAR NKCELLS                      | Refractory B-cell lymphoma                                                           |
| Anti-Mesothelin CAR NK cells                     | Epithelial ovarian cancer                                                            |
| Anti-PSMA CAR NK cells                           | Castration-resistant prostate cancer                                                  |
| CAR-NK cells targeting NKG2D ligands             | Solid tumors                                                                         |
| ROBO1 CAR-NK cells                              | Solid tumors                                                                         |
| BCMA CAR-NK 92 cells                            | Multiple myeloma                                                                    |
| Anti-CD33 CAR-NK cells                          | Acute myelogenous leukemia, AML, AML with maturation, AML without maturation         |
| Anti-CD19 CAR-NK cells                          | ALL, CLL, Follicular lymphoma, Mantle cell lymphoma, B-cell prolymphocytic leukemia, Diffuse large cell lymphoma |
| BiCAR-NK cells (ROBO1 CAR-NK cells)              | Pancreatic cancer                                                                    |
| BiCAR-NK/T cells (ROBO1 CAR-NK cells)            | Malignant tumor                                                                      |

Current clinical trials that involved CAR-NK cells. CD22 and CD19, B cell receptors; Mesothelin, protein expressed in mesothelial cells; PSMA, prostate-specific membrane antigen; ROBO1, roundabout homolog 1; BCMA, B-cell maturation antigen; CD33, myeloid cell antigen; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia.
myeloma (110) and advanced renal cell cancer and melanoma patients (111).

NK-92 cells may be genetically engineered such that they have enhanced anti-tumor properties. For example, Yang et al. engrafted a dominant negative TGFβR2 onto NK-92 cells (112) rendering them insensitive to TGFβ. Once transferred to a mouse model of lung cancer, there was reduced tumor proliferation and lung metastasis, while the modified NK-92 cells produced more IFNγ, all of which culminated in increased survival rates. Similarly, Wang et al. genetically engineered the TGFβR2 such that the extracellular and transmembrane region remained intact, yet the intracellular signaling region consisted of intracellular domain of the activating receptor NKD2GD. These NK-92 cells then had enhanced IFNγ production, increased killing capacity in vivo and reduced the differentiation of CD4+ T cells into Treg cells (113). Beyond TGFβ signaling, NK-92 cells are also amenable to CAR engineering. Oelsner et al. transduced NK-92 cells with CD19 and human CD3ζ. These CAR-NK-92 cells were able to kill tumor cells which their parent cells were resistant to. Furthermore, and in contrast to their non-CAR counterparts, they inhibited progression of an in vivo model of lymphoma (114). Indeed, the potential to develop these NK-92 cells as “off the shelf” immunotherapy is immense. Basic research which unveils how cancer impacts NK cells, and how metabolism and cytokines such as TGFβ play into this, will allow us to unlock the full potential of these novel technologies.

Reimagining NK Cell Mediated Antibody Therapy

NK cell targeted therapy has been in use in the clinic since Rituximab was given FDA approval in 1997 for the treatment of lymphoma. Rituximab, in addition to other antibody therapies such as anti-GD2 and Trastuzumab (for neuroblastoma and Her-2+ breast cancer, respectively), bind to their cognate tumor antigens upon infusion into the patient. NK cells then bind to the Fc region of the antibody via CD16 which initiates ADCC and subsequent killing of the tumor cell. While they have improved survival of these cancers significantly, there is still much room for improvement. For example, combining Herceptin with paclitaxel or with Adriamycin plus cyclophosphamide increased overall survival of HER2+ breast cancer patients from 17–41 and 42–56%, respectively (115). While this was a great medical advancement, 41 and 56% overall survival rates are still quite poor. Further, there are many patients who do not respond at all to antibody treatment. As we recently showed that NK cells are metabolically dysfunctional in breast cancer patients (54), we can seek to devise ways to combine current antibody treatments with approaches to increase the metabolism and thus function of the NK cells, thereby improving overall effectiveness of the treatment. One possibility is to harvest patient PBMC, expand the NK cells and increase their metabolism e.g., by inclusion of an inhibitor of TGFβ signaling in cultures. Cells can then be reinfused back into the patient along with antibody therapy. Indeed, TGFβ has been shown to inhibit human NK cell ADCC (30), so we can expect these treated autologous NK cells to also have boosted ADCC activity, which is essential for the antibody therapy to work.

There is also the possibility to accept the fact that patient immune cells are dysfunctional, and to instead use allogeneic adoptive NK cell therapy to mediate the ADCC required for effective antibody mediated therapy. While allogeneic donor NK cells are one possibility, CAR-NK cells could also be an excellent tool in this setting. Jochems et al. engineered NK-92 cells to express the high affinity CD16 receptor (116). These CAR-NK-92 cells then had increased anti-tumor activity and had higher rates of ADCC when used with Herceptin, Cetuximab, and Pertuzumab in vitro. Targeting metabolism to improve function and survival of these allogeneic cells in a hostile cancer environment in vivo might extend the therapeutic window prior to their eventual rejection. We predict that cell models such as CAR-NK-92 cells could be effective in the treatment of cancers which currently use antibody therapy in their first line of treatment (breast cancer, lymphoma, neuroblastoma etc.). If CAR-NK-92 cells could be developed as “off the shelf” treatment, co-treatment of patients with antibody and CAR-NK-92 cells might become a reality in the years to come.

CONCLUDING REMARKS

Immunometabolism has reinvigorated many aspects of immunology and raised many questions that are now under active investigation. We now know that metabolic dysfunction of immune cells is a key mechanism underlying many human pathologies, including autoimmune disease, infection, obesity and cancer. It is clear that TGFβ treatment inhibits NK cell function and metabolism. In mice, this is mTORC1 dependent, yet in humans it seems that only chronic TGFβ treatment is mTORC1 dependent. Indeed, the interplay between TGFβ and mTORC1 warrants further investigation. It will be exciting to discover what impact TGFβ might have on other important aspects of mitochondrial biology such as ROS production/signaling, mitochondrial dynamics, ER and calcium signaling and much more. Lessons from the literature on other cell types suggest that TGFβ might impact all of these currently unknown aspects of NK metabolism.

The advances that have been made in adoptive cellular therapy and genetic engineering in recent years will no doubt pave the way to new immune therapeutic strategies that are tailored according to cancer type, stage, genotype, immune infiltration and increasingly important, metabolism. Future work must focus on unraveling the molecular pathways that connect these once distant fields of immunology and metabolism, so that we can piece together the best ways to successfully translate immunometabolism to the clinic.

AUTHOR CONTRIBUTIONS

The article was written by KS and CG. Figures were mainly prepared by KS.
FUNDING
KS was funded by NCRC grant A/18/5. CG was funded NCRC grant A/18/5 and HRB HRA-POR-2015-1061.

ACKNOWLEDGMENTS
Images from the Servier Medical ART database were used when making the figures.
proliferation of bone marrow-derived adult human mesenchymal stem cells.\cite{GenesDev}(2006)20:666–74. doi:10.1101/gad.1388806

35. Kamiya Y, Miyazono K, Miyazawa K. Smad7 inhibits transforming growth factor-beta family type I receptors through two distinct modes of interaction.\cite{J Biol Chem}(2010)285:30804–13. doi:10.1074/jbc.M110.141210

36. De Boeck M, ten Dijke P. Key role for ubiquitin protein modification in TGFβ signal transduction.\cite{Ups J Med Sci}(2012)117:153–65. doi:10.3109/03009734.2012.654858

37. Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology.\cite{Cold Spring Harb Perspect Biol}(2016)8:a021873. doi:10.1101/cshperspect.a021873

38. David CJ, Massague J. Contextual determinants of TGFβ action in development, immunity and cancer.\cite{Nat Rev Mol Cell Biol}(2018)19:419–35. doi:10.1038/s41580-018-0007-0

39. Zhang YE. Non-Smad pathways in TGF-beta signaling.\cite{Cell Res}(2009)19:128–39. doi:10.1038/cr.2008.328

40. Griswold-Prenner I, Kamibayashi C, Maruoka EM, Mumby MC, Derynck R. Physical and functional interactions between type I transforming growth factor beta receptor and Balpha, a WD-40 repeat subunit of phosphatase 2A.\cite{Mol Cell Biol}(1998)18:6595–604. doi:10.1128/MCB.18.11.6595

41. Sebestyen A, Hajdu M, Kis L, Barna G, Kopper L. Smad4-independent, PP2A-dependent apoptotic effect of exogenous transforming growth factor beta 1 in lymphoma cells.\cite{Cell Res}(2007)3:13567–74. doi:10.1016/j.jexre.2007.05.028

42. Zhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, et al. TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis.\cite{Mol Cell}(2013)51:559–72. doi:10.1016/j.molcel.2013.07.014

43. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β.\cite{Mol Cell Biol}(2008)31:918–24. doi:10.1074/mc07.0364010

44. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, et al. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.\cite{PLoS ONE}(2011)6:e22842. doi:10.1371/journal.pone.0022842

45. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of Nkp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.\cite{Proc Natl Acad Sci USA}(2003)100:4120–5. doi:10.1073/pnas.0730640100

46. Viel S, Marcais A, Guiramares FS, Loftus R, Rabilloud J, Grau M, et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.\cite{Sci Signal}(2016)9:e2016184. doi:10.1126/scisignal.aad1884

47. Zaitz-Bittencourt V, Finlay DK, Gardiner CM. Canonical TGF-β signaling pathway represses human NK cell metabolism.\cite{J Immunol}(2018)200:3934–41. doi:10.4049/jimmunol.1700416

48. Rahimi RA, Andrianisifanana M, Wilkes MC, Edens M, Kottjom TJ, Blenis J, et al. Distinct roles for mammalian target of rapamycin complex 2 in the fibroblast response to transforming growth factor-beta.\cite{Cancer Res}(2009)69:84–93. doi:10.1158/0008-5472.CAN-08-2146

49. Selvarajah B, Azuelos I, Plate M, Guillotin D, Forty EJ, Contento G, et al. Repression of GSK3 restores NK cell cytotoxicity in AML patients.\cite{Oncotarget}(2019)10:6968–7003. doi:10.18632/oncotarget.11888

50. Fu H, Hu Z, Wen J, Wang K, Liu Y. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways.\cite{Acta Biochim Biophys Sin.}(2009)41:648–56. doi:10.1093/abbs/gmp053

51. Li J, Shen C, Wang X, Lai Y, Zhou K, Li P, et al. Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis.\cite{BMJ Cancer}(2019)19:6911. doi:10.1136/bmj.s12885-019-9157-7

52. Saito H, Osaki T, Ikeguchi M. Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer.\cite{Gastric Cancer}(2012)15:27–33. doi:10.s10120-011-0059-8

53. Choi SI, Lee SH, Park JY, Kim KA, Lee EJ, Lee SY, et al. Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: a prospective pilot study.\cite{Onco Targets Ther.}(2019)12:1661–9. doi:10.2147/OTT.S194273

54. Almutairi SM, Ali AK, He W, Yang DS, Ghorbani P, Wang L, et al. Interleukin-18 up-regulates amino acid transporters and facilitates amino acid-induced mTORC1 activation in natural killer cells.\cite{J Biol Chem}(2019)294:6464–55. doi:10.1074/jbc.RA118.005892

55. Parmeswaran R, Ramakrishnan P, Moreton SA, Xia Z, Hou Y, Lee DA, et al. Repression of GSK3 restores NK cell cytotoxicity in AML patients.\cite{Nat Commun}(2016)7:11154. doi:10.1038/ncomms11154

56. Utrawar L, Gao B, Ingram AJ, Krepsinsky JC. SREBP-1 activation by glucose mediates TGF-β upregulation in mesangial cells.\cite{Am J Physiol Renal Physiol.}(2012)302:F329–41. doi:10.1152/ajprenal.00136.2011

57. Van Krieken R, Chen G, Gao B, Read J, Al Saleh HA, Li R, et al. Sterol Regulatory Element Binding Protein (SREBP)-1 is a novel regulator of the Transforming Growth Factor (TGF)-beta receptor 1 (TbetaRI) through exosomal secretion.\cite{Cell Signal.}(2017)29:158–67. doi:10.1016/j.cellsig.2016.11.004

58. Chen G, Wang T, Utrawar L, vanKrieken R, Li R, Chen X, et al. SREBP-1 is a novel mediator of TGFβ1 signaling in mesangial cells.\cite{J Mol Cell Biol.}(2014)6:516–45. doi:10.1093/jmcb/jmu041

59. Moloney JN, Cotter TG. ROS signalling in the biology of cancer.\cite{Semin Cell Dev Biol.}(2018)80:50–64. doi:10.1016/j.semcdb.2017.05.023

60. Toth MB, Mavinkurve M, Carolan E, Krilen D, O'Brien EC, Little MA, et al. NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient.\cite{JCI Insight.}(2017)2:94939. doi:10.1172/jci.insight.94939
Slattery and Gardiner

TGFβ and NK Cell Metabolism

72. Efimova O, Szankasi P, Kelley TW. Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells. PLoS ONE. (2011) e16013. doi: 10.1371/journal.pone.0016013

73. Stockis J, Colauti D, Doulie PG, Lucas S. Membrane protein GARP is a receptor for latent TGF-β on the surface of activated human Treg. Eur J Immunol. (2012) 42:3135–42. doi: 10.1002/eji.201240202

74. Sturrock A, Huecksteadt TP, Norman K, Sanders K, Murphy TM, Chitano P, et al. Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in hypertrrophic human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. (2007) 292:1543–55. doi: 10.1152/ajplung.00430.2006

75. Michaeloudes C, Sukkar MB, Khorasani NM, Bhavsar PK, Chung KF. TGF-β regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. (2011) 300:L295–304. doi: 10.1152/ajplung.00134.2010

76. Jain M, Rivera S, Monclus EA, Synenki L, Zirk A, Eisenbart J, et al. Flisiak R, Prokopowicz D, Jaroszewicz J, Flisiak I. Plasma transforming growth factor-beta and Interleukin-10 synergistically regulate Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. (2011) 300:L295–304. doi: 10.1152/ajplung.00134.2010

77. Yoon YS, Lee JH, Hwang SC, Choi KS, Yoon G. TGF beta1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells. Oncogene. (2005) 24:1895–903. doi: 10.1038/sj.onc.1208262

78. Iain M, Rivera S, Monclus EA, Synenki L, Zirk A, Eisenbart J, et al. Mitochondrial reactive oxygen species regulate transforming growth factor-beta signaling. J Biol Chem. (2013) 288:770–7. doi: 10.1074/jbc.M112.431973

79. Wu J, Niu J, Li X, Wang X, Guo Z, Zhang F. TGF-beta1 induces senescence of bone marrow mesenchymal stem cells via increase of mitochondrial ROS production. BMC Dev Biol. (2014) 14:21. doi: 10.1186/1471-213X-14-21

80. Yang GL, Xu LM, Yao HY, Wang HS, Jiang XL, Li W, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. (2017) 45:e124–31. doi: 10.1097/CCM.0000000000002053

81. Morgan RA, Yang JG, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. (2010) 18:843–51. doi: 10.1038/mt.2010.24

82. Yvon ES, Burga R, Powell A, Cruz CR, Fernandes R, Barere C, et al. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy. (2017) 19:408–18. doi: 10.1016/j.jcyt.2016.12.005

83. Zhao Y, Hu J, Li R, Song J, Kang Y, Liu S, et al. Enhanced NK cell adaptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-beta signaling pathway. Onco Targets Ther. (2015) 8:1553–9. doi: 10.2147/OTT.S28616

84. Daher M, Basar R, Shaim H, Goldemir E, Upreti N, Kontoyiannis A, et al. The TGF-β/SMAD signaling pathway as a mediator of NK cell dysfunction and immune evasion in myelodysplastic syndrome. Blood. (2017) 130:505. doi: 10.1038/leu.2015.327

85. Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. (2015) 13:277. doi: 10.1186/s12967-015-0632-8

86. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. (2005) 105:3051–7. doi: 10.1182/blood-2004-07-2974

87. Curti A, Ruggieri L, D’Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. (2011) 118:3273–9. doi: 10.1182/blood-2011-01-329508

88. Bjorklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, et al. Complete remission with reduction of high-risk clones following haploidentical NK cell therapy against MDS and AML. Clin Cancer Res. (2018) 24:1834–44. doi: 10.1158/1078-0432.CCR-17-1319

89. Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Haro I, Bertran E, et al. Role of the Transforming Growth Factor-beta in regulating hepatocellular carcinoma oxidative metabolism. J Hepatol. (2017) 67:12486. doi: 10.1016/j.jhep.2017.04.009

90. Locatelli F, Pende D, Falco M, Della Chiesa M, Moretta A, Moretta L. Complete remission with reduction of high-risk clones following haploidentical HSCT to cure high-risk acute leukemia. J Immunol. (2018) 199:331–2. doi: 10.4049/jimmunol.1800782

91. Li Y, Hermanson DL, Moriaty RS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. (2018) 23:181–92.e185. doi: 10.1016/j.stem.2018.06.002

92. Bueno P, Sharma K,_CSRods G, Zhu Y, Hajnoczky G. Uncoupling of ER-mitochondrial communication by transforming growth factor-beta. Am J Physiol Renal Physiol. (2008) 295:F1303–12. doi: 10.1152/ajprenal.00182.2013

93. Sayeed A, Meng Z, Luciani G, Chen LC, Bennington JL, Darkeei SH. Negative regulation of UCP2 by TGFβ signaling characterizes low and intermediate-grade primary breast cancer. Cell Death Dis. (2010) 1:e53. doi: 10.1038/cddis.2010.30

94. Soukopova J, Malfettone A, Hyrossova P, Hernandez-Alvarez MJ, Penuelas-Haro I, Bertran E, et al. Role of the Transforming Growth Factor-beta in regulating hepatocellular carcinoma oxidative metabolism. Sci Rep. (2017) 7:12486. doi: 10.1038/s41598-017-1287-y

95. Buck MD, O’Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial dynamics controls T cell fate through mitochondrial programming. Cell. (2016) 166:63–76. doi: 10.1016/j.cell.2016.05.035

96. Komai T, Inoue M, Okamura T, Morita K, Iwasaki Y, Sumitomo S, et al. Transforming growth factor-beta and Interleukin-10 synergistically regulate humoral immunity via modulating mitochondrial signals. Front Immunol. (2018) 9:1364. doi: 10.3389/fimmu.2018.01364

97. Pacher P, Sharma K, CORSods G, Zhu Y, Hajnoczky G. Uncoupling of ER-mitochondrial communication by transforming growth factor-beta. Am J Physiol Renal Physiol. (2008) 295:F1303–12. doi: 10.1152/ajprenal.00182.2013

98. Maul-Pavicic A, Chiang SC, Rensing-Ehl A, Jessen B, Fauriat C, Wood SM, et al. ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc Natl Acad Sci USA. (2011) 108:3324–9. doi: 10.1073/pnas.1013285108
107. Quintarelli C, Sivori S, Caruso S, Carломagno S, Boffa I, Orlando D, et al. CD19 redirected CAR NK cells are equally effective but less toxic than CAR T cells. *Blood*. (2018) 132:3491. doi: 10.1182/blood-2018-99-118005

108. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. *Leukemia*. (2018) 32:520–31. doi: 10.1038/leu.2017.226

109. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. *Cytotherapy*. (2013) 15:1563–70. doi: 10.1016/j.jcyt.2013.06.017

110. Williams BA, Law AD, Routy B, denHollander N, Gupta V, Wang XH, et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. *Oncotarget*. (2017) 8:89256–68. doi: 10.18632/oncotarget.19204

111. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. *Cytotherapy*. (2008) 10:625–32. doi: 10.1080/14653240802301872

112. Yang B, Liu H, Shi W, Wang Z, Sun S, Zhang G, et al. Blocking transforming growth factor-beta signaling pathway augments antitumor effect of adoptive NK-92 cell therapy. *Int Immunopharmacol*. (2013) 17:198–204. doi: 10.1016/j.intimp.2013.06.003

113. Wang Z, Guo L, Song Y, Zhang Y, Lin D, Hu B, et al. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-betaRII and NKG2D. *Cancer Immunol Immunother.* (2017) 66:537–48. doi: 10.1007/s00262-017-1959-1

114. Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. *Cytotherapy*. (2017) 19:235–49. doi: 10.1016/j.jcyt.2016.10.009

115. Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thelu MA, Sturm N, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. *J Hepatol*. (2009) 51:458–67. doi: 10.1016/j.jhep.2009.05.030

116. Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM II, Greiner JW, Padget MR, et al. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. *Oncotarget*. (2016) 7:86359–73. doi: 10.18632/oncotarget.13411

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Slattery and Gardiner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.